Verrica Pharmaceuticals Inc. (VRCA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.9200 |
| Open | 6.0500 |
| Bid | 1.9600 x 1800 |
| Ask | 2.0200 x 2900 |
| Day's Range | 5.8200 - 6.1200 |
| 52 Week Range | 1.8000 - 14.7890 |
| Volume | |
| Avg. Volume | 285,396 |
| Market Cap | 55.038M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4570 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
- Zacks
Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA
Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.
- Benzinga
RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next?
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform and lowered the price target from $16 to $4. The analysts note that the issues fall outside of the VP-102's purview. But as per a follow-up call with management, these recurrent offenses highlight the challenges at play with a m
- MarketWatch
Verrica's stock slides after getting second complete response letter from FDA
Shares of Verrica Pharmaceuticals Inc. tumbled 54.5% in premarket trading on Wednesday, the day after the company told investors it received a complete response letter from the Food and Drug Administration relating to the application for the company's experimental treatment for molluscum contagiosum, an infection caused by a poxvirus. The letter cited problems with the contract manufacturing organization Sterling Pharmaceuticals Services LLC, which made the bulk solution drug product used in the
